INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.

TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, a reputable journal published by GAKUSHIN PUBL CO, serves as an essential resource for researchers and professionals engaged in the evolving fields of glycoscience and glyotechnology. Established in 1989, this journal has progressively focused on stimulating discussions and disseminating pivotal findings that impact various applications in biochemistry and organic chemistry. With an impressive converge covering decades up to 2024, the journal has carved a niche within the scientific community, despite currently being classified in the lower quartiles (Q4) for its respective categories in 2023. This designation underscores the potential for growth and enhanced visibility within research networks. While it currently operates under a subscription-based model, TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY remains committed to fostering innovation and interdisciplinary collaboration, providing a critical platform for the exploration of glycan structures and functions. Located in Tokyo, Japan, the journal invites contributions that contribute to the future direction of glycoscientific research and its applications.

EMBO REPORTS, published by WILEY, is a premier journal in the fields of Biochemistry, Genetics, and Molecular Biology, recognized for its rigorous peer-review process and impactful scientific contributions. Established in the year 2000 in the United Kingdom, this journal has maintained a stellar reputation, reflected in its consistent positioning within the Q1 category across these disciplines as of 2023. EMBO REPORTS excels in disseminating high-quality and timely research that addresses fundamental questions and challenges in molecular biology and genetics, making it an invaluable resource for researchers, professionals, and students. With impressive Scopus rankings, including Genetics at the 32nd rank and a 90th percentile placement, it fosters an environment for scholarly exchange and advances in knowledge. While Open Access options are not available, the journal continues to enhance its impact through traditional subscription models, thereby maintaining wide visibility in the scientific community. Its ongoing evolution promises continued relevance and influence until at least 2024.

PROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.

The EMBO JOURNAL, published by Wiley in Germany, is a renowned scientific journal that has been at the forefront of research in the fields of biochemistry, genetics, and molecular biology since its inception in 1982. With an impressive convergence of contributions leading up to 2024, this journal is recognized for its high impact, reflected in its Q1 rankings across multiple categories including Immunology, Molecular Biology, and Neuroscience. It holds a prestigious place in the academic community, standing out with an exemplary Scopus ranking of #3 in General Immunology and Microbiology and #6 in General Neuroscience, making it a critical resource for researchers, professionals, and students alike. The journal aims to publish transformative research that sheds light on the underlying mechanisms of biological processes, thus advancing our understanding of health and disease. While currently not offering open access, the EMBO JOURNAL continues to facilitate a rich exchange of knowledge through its rigorous peer-review process and commitment to excellence.

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

FEBS LETTERS, published by Wiley, is a prestigious journal that has firmly established its place in the fields of biochemistry, biophysics, genetics, molecular biology, cell biology, and structural biology. With an esteemed history dating back to 1968, this journal continues to be a vital resource for researchers and professionals involved in the biological sciences. It boasts impressive quartile rankings, including Q1 statuses in several categories such as Biochemistry and Genetics, reflecting its high impact factor and significant contribution to scientific discourse. FEBS LETTERS provides a platform for innovative findings and critical reviews, fostering the exchange of knowledge and ideas within the scientific community. Although it operates under a subscription model, the journal ensures broad dissemination of groundbreaking research through its rigorous peer-review process. The vibrant discussions encouraged by articles published in FEBS LETTERS aim to inspire current and future generations of scientists to push the boundaries of biological understanding, making it an indispensable resource for anyone dedicated to advancing their knowledge in these dynamic fields.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

GLYCOBIOLOGY is a premier journal published by Oxford University Press Inc., focusing on the multidisciplinary field of glycoscience. With an ISSN of 0959-6658 and an E-ISSN of 1460-2423, this journal has established itself as an essential resource for researchers, professionals, and students interested in the biochemical aspects of glycan structures, functions, and interactions. The journal boasts a Q1 rank in the biochemistry category for 2023, placing it in the top-tier of scholarly publications, and achieving a percentile rank of 71st out of 438 in the Scopus database for biochemistry, genetics, and molecular biology. Covering integral aspects of glycobiology since its inception in 1990, GLYCOBIOLOGY offers a robust platform for the dissemination of novel research findings, reviews, and methodologies that advance the understanding of glycan-related processes and their implications in health and disease. Researchers can access high-quality content that not only promotes scientific discourse but also pushes the boundaries of knowledge in this vital field.